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Abstract
Purpose—Cancer-related fatigue (CRF) is a disruptive symptom for many survivors. Despite 
promising evidence for efficacy of Mindfulness-Based Stress Reduction (MBSR) in reducing CRF, 
no trials comparing it to an active comparator for fatigued survivors have been published. The 
purpose of this trial was to compare MBSR to psychoeducation for CRF and associated symptoms.
Methods—Breast (n=60) and colorectal (n=11) cancer survivors (stage 0–III) with clinically 
significant CRF after completing chemotherapy and/or radiation therapy an average of 28 months 
prior to enrollment were randomized to MBSR or psychoeducation/support groups (PES). MBSR 
focused on mindfulness training; PES focused on CRF self-management. Outcomes included CRF 
interference (primary), CRF severity and global improvement, vitality, depression, anxiety, sleep 
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disturbance, and pain. Outcomes were assessed at baseline (T1), post-intervention (T2), and 6-
month follow-up (T3) using intent-to-treat analysis.
Results—Between-group differences in CRF interference were not significant at any time point; 
however, there was a trend favoring MBSR (d=−0.46, p=0.073) at T2. MBSR participants reported 
significantly greater improvement in vitality (d=0.53, p=0.003) and were more likely to report 
CRF as moderately-to-completely improved compared to the PES group (χ2 (1)=4.1765, p=0.041) 
at T2. MBSR participants also reported significantly greater reductions in pain at T2 (d=0.53, 
p=0.014). In addition, both MBSR and PES produced moderate-to-large and significant within-
group improvements in all fatigue outcomes, depression, anxiety, and sleep at T2 and T3 
compared to T1.
Conclusion—MBSR and PES appear efficacious for CRF and related symptoms. Larger trials 
including a usual care arm are warranted.
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BACKGROUND
Fatigue is the most common and distressing cancer-related symptom [1,2], affecting 
approximately 30% of breast and colorectal cancer survivors years into disease-free 
survivorship [3,4]. Cancer-related fatigue (CRF) negatively impacts survivors’ quality of 
life[5] and ability to work [6], and places survivors at increased risk for cancer recurrence 
[7]. Moreover, CRF is drastically under-treated [8], with <15% of fatigued patients reporting 
having received any guidance in CRF management from their health care team [9].
Clinical practice guidelines for CRF recommend symptom management [10]. Mindfulness-
Based Stress Reduction (MBSR) is a non-pharmacologic intervention that has shown 
promise in the treatment of CRF [11–13]. MBSR is a group meditation intervention that 
provides experiential training in mindfulness, a non-judging mental state whereby one 
attends to and purposefully manages one’s awareness of what is happening in the present 
moment. The goal of MBSR is not necessarily to decrease symptom severity, but to enhance 
survivors’ ability to live with their symptoms in a non-reactive way, thereby reducing 
symptom-related interference with quality of life. Recent meta-analyses have established 
MBSR as efficacious in improving mental health outcomes in cancer [14–16]. Systematic 
reviews in adults with cancer [17,18,15] and in non-cancer populations [19,20] have 
concluded that mindfulness-based interventions are promising but require further 
investigation, particularly with respect to treating fatigue and its correlates [1,21]. Although 
clinical practice guidelines added MBSR as an evidence-based intervention for fatigue 
following cancer treatment in 2014 [10], to date only trials comparing MBSR to wait-list 
controls on fatigue outcomes have been conducted [11–13]. Of these, only one used fatigue 
as the primary outcome of the trial and enrolled participants based on presence of clinically 
significant fatigue. In that trial, Johns and colleagues reported that the MBSR group 
experienced large post-intervention improvements in fatigue interference, fatigue severity, 
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and vitality compared to the wait list group, and the improvements were maintained at 1- 
and 6-month follow-up [11].
Because the impact of MBSR on CRF has already been evaluated using wait-list controls, a 
necessary step to establish the specific effects of MBSR [22] is to conduct a more rigorous 
trial comparing MBSR specifically targeting CRF to another active treatment. In the current 
trial, we employed an active treatment control group intended to help rule out the possibility 
that placebo or related non-specific effects might be responsible for MBSR’s beneficial 
impact. Therefore, the aim of the current trial was to determine the effect size of MBSR 
compared to an active treatment in reducing fatigue and associated symptoms among cancer 
survivors following chemotherapy and/or radiotherapy. Because it is recommended as a 
treatment for CRF [10] and prior research has shown it is efficacious in treating CRF and its 
correlates [23–25], psychoeducation and support (PES) was selected as the active 
comparator for this study.
METHODS
Design
This was a 2-arm randomized clinical pilot trial. Study procedures were approved by the 
Indiana University and Community Health Network institutional review boards. Written 
informed consent was obtained from all participants. The study was funded by the Walther 
Cancer Foundation and the Indiana Clinical and Translational Sciences Institute. The study 
is registered with ClinicalTrials.gov (NCT01919853).
Participants
Breast (n=60) and colorectal (n=11) cancer survivors (BCS and CRCS, respectively) with 
persistent fatigue were consecutively recruited over 5 months in 2012–2013 from clinics 
affiliated with a National Cancer Institute-designated cancer center and through tumor 
registry mailings. BCS and CRCS were chosen as populations of interest as they are two of 
the most prevalent cancer diagnoses within our setting.
Individuals were told the study purpose was to test two potentially helpful behavioral 
treatments for CRF. Individuals were eligible if they were age 18 or older, had a first-time 
diagnosis of non-metastatic (stages 0–III) breast or colorectal cancer treated with 
chemotherapy and/or radiation therapy, and had clinically significant CRF (Fatigue 
Symptom Inventory severity composite ≥ 4) [26] that had persisted for at least 2 months. 
Individuals were excluded if they had received any cancer treatment (i.e., chemotherapy, 
radiation therapy, or surgery) less than 3 months or more than 5 years prior to enrollment 
(current endocrine therapy for breast cancer was allowed), reported severe depressive 
symptoms (Patient Health Questionnaire-8 score ≥ 20) [27], or reported past participation in 
a mindfulness class and/or ongoing meditation practice.
Randomization and Blinding
Eligible participants attended a group enrollment session, including completion of baseline 
surveys, and randomization to MBSR or PES. The allocation ratio was 1:1, with the 
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sequence generated by coin toss in randomly varied block sizes of 4 to 6 and concealed in 
opaque sequentially-numbered envelopes. Participants and research assistants were blinded 
to the allocation sequence. Outcomes were self-reported on study questionnaires, to which 
group facilitators lacked access. Participants were blinded to study hypotheses and had no 
knowledge of the content of the course to which they were not assigned.
Interventions
Participants in both interventions met for 2 hours each week for 8 weeks. The difference 
between the interventions was the active component of guided meditation in MBSR; topics 
related to mindfulness, meditation, and relaxation were not included in the PES intervention. 
Groups averaged 10 participants each to ensure equal amounts of time and attention. To limit 
contamination, groups met in separate locations.
Mindfulness-Based Stress Reduction (MBSR)—MBSR provides guided training 
during class and through audio recordings outside of class on mindfulness meditation 
practices (i.e., body scan, sitting meditation, hatha yoga, walking meditation, and 
compassion meditation). Through these practices, present-centered awareness is enhanced, 
facilitating non-reactive and non-judgmental acceptance of thoughts, feelings, and bodily 
sensations [15,18,28]. Relating to symptoms such as fatigue in this adaptive way has been 
shown to reduce symptom-related interference with quality of life [29]. MBSR was 
delivered in a manner consistent with the standard MBSR curriculum [30], tailored to the 
needs of fatigued survivors. Adaptations included 2-hour classes, no retreat, brief 
psychoeducation related to CRF, a 10-minute bedtime body scan to support rest, and shorter 
guided home practices (20 min). Participants tracked daily meditation practices on weekly 
logs. Notably, the MBSR intervention implemented in the present study was highly similar 
to the MBSR intervention implemented in our earlier study with fatigued post-treatment 
cancer survivors comparing MBSR to wait-list control [11]. MBSR instructors were a 
physician and a doctoral-level clinical health psychologist with 9 and 3 years of MBSR 
teaching experience, respectively. Further details on MBSR for CRF are published elsewhere 
[11]. A description of the MBSR sessions used in this study is presented in Table 1.
Psychoeducation and support (PES)—To provide a rigorous test of MBSR effects, a 
PES group intervention was included as an active comparator. The goal of PES is to educate 
and support patients to better cope with the side effects of their illness. For cancer survivors, 
PES programs include group discussions of CRF and its impact on psychological and social 
functioning; sharing, listening to, and affirming patients’ CRF-related experiences; and 
offering evidenced-based tips and strategies for managing CRF (e.g., sleep, nutrition, 
exercise) [31].
The study team developed a manualized PES intervention, in accordance with PES programs 
used in other published studies of CRF [23]. Specific topics were addressed each week, and 
sessions included sharing of experiences living with CRF and strategies for CRF self-
management. The details of each 8 week session are presented in Table 2. For between-
session home practice, participants received supplemental readings on fatigue self-
management from After Cancer Treatment: Heal Faster, Better, Stronger [32], as well as the 
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American Cancer Society, American Society of Clinical Oncology, National Cancer 
Institute, and CURE Magazine websites. Participants tracked time spent doing reading 
assignments and other self-care strategies discussed in class on weekly logs. PES facilitators 
were master’s level social workers each with approximately 4 years of experience 
facilitating PES groups. Participants in PES were provided with information on how to 
access MBSR courses at the end of the study.
Treatment Fidelity
Fidelity to MBSR and PES was ensured through the use of standardized manuals and audio 
recordings and evaluation of sessions for adherence to the protocol using checklists created 
for each intervention condition. Mean treatment fidelity ratings across a randomly selected 
25% of sessions were 85.1% for MBSR facilitators and 95.8% for PES facilitators.
Measures
Demographic data collected included gender, race, educational level, employment status, 
marital status, and income level, as determined by participants’ response to the question, 
“When you consider your household income from all sources today, would you say that you 
are comfortable, have just enough to make ends meet, or not enough to make ends meet.” 
Patient-reported outcomes were assessed on printed study surveys at baseline (T1), post 
intervention (T2), and 6 months later (T3) at the study site. Intent-to-treat participants 
completed T2 and T3 surveys by mail.
Primary Outcome—The Assessing the Symptoms of Cancer using Patient-Reported 
Outcomes (ASCPRO) group [33] recommends selecting CRF measures based upon study 
and intervention intent (e.g., reducing the negative impact of fatigue on functioning). Thus, 
fatigue interference was selected as the primary outcome, as the intent of MBSR is to reduce 
symptom-related functional interference. Prior studies of the effects of the active comparator 
have included fatigue interference among their outcomes [23] as interference tends to be of 
greater concern to survivors than the presence or severity of fatigue [34].
The 7-item interference subscale of the Fatigue Symptom Inventory (FSI) [35] was used in 
this study to assess the degree to which fatigue has interfered with functioning across 
multiple domains (e.g., general activity level, ability to bathe/dress, work, relationships, 
mood) over the past week. Items are rated on 11-point scales (0=no interference; 
10=extreme interference) and then averaged.
Secondary Outcomes—Fatigue severity was assessed using the 4-item FSI severity 
subscale [35]. FSI severity scores ≥ 3 (range 0 – 10) are considered clinically significant 
[26]. Vitality was measured with the 4-item SF-36 Vitality Scale [36]. Scores range from 0 
to 100, with higher scores indicating greater vitality. Vitality scores ≤ 45 are indicative of 
clinically-significant CRF [26]. Fatigue global improvement was assessed with a single item 
asking respondents to rate their CRF compared to when they started the study, with the 
options being worse, about the same, or a little, somewhat, moderately, a lot, or completely 
better [37]. Additional secondary outcome measures included the Patient Health 
Questionnaire 8-item depression scale (PHQ-8) [27] and 7-item Generalized Anxiety 
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Disorder scale (GAD-7) [38], the 7-item Insomnia Severity Index (ISI) [39], and a 3-item 
version of the Brief Pain Inventory [40].
Additional Outcomes—At the beginning of session 2, participants were asked to 
complete a 5-item expectancy-credibility scale adapted from Devilly and Borkovec that 
measures participants’ perceptions of the expected benefits and credibility of treatment on a 
0–9 scale [41]. Participants’ overall satisfaction with the study was rated at T3 on an 11-
point scale (0=not at all satisfied; 10=completely satisfied). Also at T3, MBSR participants 
were asked to report the average number of days per week, if any, they had continued to 
participate in mindfulness practice, both formal (e.g., body scan, sitting practice, yoga) and 
informal (doing everyday activities mindfully).
Statistical Power
Because this was a pilot study, the principal aim was to estimate an effect size for a 
definitive phase 3 randomized clinical trial. The sample size of 71 had 80% power to detect 
a medium-to-large effect size (0.65–0.70) difference between means for tests of between-
group efficacy.
Statistical Analysis
Intent-to-treat analyses were conducted using imputation to fill in missing data according to 
randomly assigned group membership regardless of degree of adherence to their 
intervention. Available data from all participants were included in the analyses regardless of 
attendance or engagement in the intervention. Groups were compared on T1 demographic 
and medical characteristics using Chi square and Fisher’s Exact tests for categorical 
variables and t-tests for continuous variables. Although there were no statistically significant 
differences between groups on these variables at p<0.05, we controlled for characteristics 
thought to be clinically/theoretically relevant in an investigation of CRF and/or those where 
the between group difference was p<0.10 [42], including cancer type and income.
Analysis of covariance (ANCOVA) was used to test efficacy by comparing MBSR to PES on 
primary and secondary outcomes at T2 and separately at T3 while adjusting for covariates 
and baseline scale scores for each variable. When computing scale scores, a person-specific 
and scale-specific mean of non-missing items was substituted for missing items if 33% or 
fewer of the scale’s items were missing. However, missing data occurred infrequently. Effect 
sizes (Cohen’s d) were calculated for each outcome variable at T2 and T3 as the 
standardized mean difference between the MBSR and PES groups divided by the pooled 
baseline standard deviation of the outcome variable. CRF global improvement (defined as 
those reporting their CRF as being moderately to completely better since T1) was compared 
at T2 and at T3 with Chi square. Between-group comparisons on expectancy-credibility and 
satisfaction were analyzed with t-tests. The paired t-test was used to assess within-group 
improvements on all outcomes for each group at T2 and T3 as compared to T1 scores on 
each variable. Within-group effect sizes were assessed by the standardized response mean 
(SRM), which is the difference between means (T1 to T2; or T1 to T3) divided by the SD of 
changes scores. Analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, 
NC).
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RESULTS
Enrollment and Attrition
As shown in Figure 1, 224 consecutive BCS and CRCS were screened for eligibility, of 
which 79 were found ineligible and excluded. Of the remaining 145 eligible survivors, 71 
(49%) agreed to participate and were enrolled in the study and randomized. Overall, 
retention exceeded 97% at T2 and 94% at T3 in both groups.
Baseline Participant Characteristics
As summarized in Table 3, the sample was predominantly female (90.1%) and white 
(70.4%), with less than a college degree (56.3%). Approximately half were employed 
(52.1%), endorsed having a comfortable income (52.1%), and were married/partnered 
(54.9%). All had received chemotherapy and/or radiation therapy, and the average time since 
completion of these treatments was approximately 2.4 years. Many BCS (46%) were taking 
endocrine therapy at enrollment. With the exception of income (p = 0.07), there were no 
statistically significant group differences in baseline characteristics.
Between-Group Intervention Effects
Primary Outcome—CRF interference did not significantly differ between groups at T2 or 
T3 (Table 4). However, there was a non-significant trend favoring MBSR (d=-0.46, p=0.073) 
at T2. The PES group experienced accumulating benefits over time, with a mean CRF 
interference score similar to the MBSR group at T3.
Secondary Outcomes—As shown in Table 4, the MBSR group demonstrated a moderate 
and significant effect size in vitality at T2 compared to the PES group (d=0.53, p=0.003). 
Although the MBSR group maintained their improvement in vitality at T3, the between-
group difference was no longer significant (d=0.27, p=0.136) because of continued 
improvement in the PES group. On the CRF global improvement item, MBSR participants 
were significantly more likely than PES participants [58.8% vs. 34.3%, respectively; χ2 
(1)=4.176, p=0.041] to report their CRF as being moderately to completely better at T2. 
Groups reported similar levels of global improvement in CRF at T3, with approximately half 
of each group [MBSR 45.5% vs. PES 54.3%; χ2 (1)=0.530, p=0.467] reporting their fatigue 
as moderately to completely better. As shown in Table 5, the MBSR group reported 
moderate and significant reduction at the end of the intervention in pain compared to PES 
participants (d=−0.50, p= 0.014). There were no significant between-group differences on 
any other secondary outcomes at any time point (Table 5).
Both groups reported high expectations that their assigned intervention would be helpful and 
that the intervention was credible on the 0–9 expectancy-credibility scale [MBSR mean 
(SD)=7.6 (1.5); PES mean (SD)=7.2 (1.5); p=0.255]. Likewise, satisfaction was rated 
similarly high across groups, with the MBSR group reporting a mean (SD) of 8.7 (1.9) 
compared to 8.4 (2.1) in the PES group (p=0.54) on the 0–10 satisfaction scale.
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Within-Group Intervention Effects
Moderate-to-large and significant within-group improvements on all fatigue outcomes were 
found at T2 and T3 compared to T1 in both MBSR and PES groups (Table 4). Participants in 
both interventions also experienced moderate-to-large and significant improvements at both 
time points on depression, anxiety, and sleep disturbance. Effects on pain were moderate and 
significant for the MBSR group at both time points and significant for the PES group only at 
T3 (Table 5).
Attendance and Home Practice
Attendance was similar between groups. MBSR participants attended an average of 5.8 
(SD=2.1) sessions compared to 6.3 (SD=1.9) for PES participants [t(68)=0.96, p=0.30]. 
Participants in both groups also reported a similar amount of time completing home practice 
assignments each week. MBSR participants reported an average of 117.6 (SD=85.9) minutes 
per week of home practice compared to 92.5 (SD=92.1) minutes per week for PES 
participants [t(69)=1.19 p=0.2398)]. At 6-month follow-up, 75.8% of MBSR participants 
reported continued “formal” mindfulness practice; however, only 36.4% reported frequent 
practice (≥3 days/week). Almost all MBSR participants (84.8%) reported continued 
“informal” mindfulness practice after completing the MBSR course.
DISCUSSION
This pilot trial revealed several important findings regarding MBSR compared to PES for 
CRF. First, there was a trend favoring MBSR on fatigue interference, and a clear advantage 
favoring MBSR in vitality and global improvement in fatigue immediately post intervention. 
However, these between group differences were not evident at 6 months follow-up as PES 
participants experienced ongoing improvements in fatigue. Second, both MBSR and PES 
participants experienced significant, moderate-to-large, within-group improvements in 
fatigue and its correlates that were maintained 6 months post intervention. As there were no 
statistically significant differences in baseline scores on fatigue or its correlates, these 
findings suggest that both interventions are efficacious in alleviating fatigue, although 
MBSR might yield results sooner than PES. Lastly, both interventions proved feasible and 
acceptable as evidenced by high rates of retention, attendance, satisfaction, and adherence to 
home practice, indicating that cancer survivors are open to participating in weekly 2-hour 
classes and daily home practice despite their persistent fatigue. The results of this pilot trial 
are rather promising as they demonstrate two potentially acceptable and efficacious 
interventions for ameliorating fatigue.
The significant between-group differences in vitality and fatigue global improvement at T2 
combined with the significant within-group fatigue improvements for MBSR at T2 and T3 
support its use as a potential treatment for CRF. These results are consistent with those of a 
recent randomized controlled trial testing an 8-week mindfulness-based intervention in 
which the mindfulness group reported significant improvements in fatigue outcomes 
compared to participants in the wait-list control group post-intervention, and these 
improvements were maintained for the mindfulness group through the 6-month follow-up 
[43]. Although our study lacked a usual care (UC) group for comparison, results of extant 
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studies strongly suggest that the persistent fatigue that defined our sample was unlikely to 
have remitted spontaneously [11,43]. These findings suggest that mindfulness may be 
efficacious in improving vitality and patients’ perceptions of fatigue.
The purpose of this pilot trail was to provide a rigorous test of MBSR, yet surprisingly this 
study also strengthened support for the use of PES interventions for CRF. In developing the 
PES intervention, we intended to provide a credible treatment that did not include 
mindfulness training and controlled for nonspecific factors (e.g., amount of social contact 
and attention from an empathic clinician) [22]. Although we expected psychoeducation to be 
helpful, we were surprised by the magnitude and durability of the within-group effect sizes 
of the PES intervention. The mechanisms by which PES interventions lead to reductions in 
fatigue and associated symptoms are unclear, but there are at least two possible explanations. 
First, the sharing of experiences and interacting with other cancer survivors within group 
sessions may have contributed to patients’ perceptions of social support and validation, a 
factor critical to helping patients adjust during survivorship [44]. In addition, our 
intervention may have fostered patients’ sense of self-efficacy, or their beliefs in their 
abilities to cope. By providing information about fatigue and potential strategies to manage 
fatigue, patients may have felt better equipped to deal with fatigue and other lingering side 
effects of cancer treatment [45]. Additional studies are needed to elucidate the mechanisms 
of PES interventions and their effects on CRF.
This pilot study had several strengths. Care was taken to match the PES intervention to 
MBSR in facilitator skill, class duration, and home practice expectations, which allowed for 
a direct comparison of the effects of MBSR relative to an active comparator. The trial also 
included a 6-month follow-up, which has been missing in most trials of integrative CRF 
treatments. A strength related to generalizability is the demographic heterogeneity of the 
sample.
This study also had limitations. There was a lack of power for efficacy testing. However, this 
pilot study was designed to estimate effect sizes for future work, which was accomplished. 
A larger trial is warranted that includes a UC arm to assess differential efficacy between 
MBSR and PES interventions compared to UC. Another limitation was the heterogeneity 
regarding cancer stage and time since completion of cancer treatment, as these variables 
could potentially contribute to differential responses to MBSR or PES. Yet, these 
characteristics were balanced between groups, and thus any potential effects likely were 
negligible. Although gender, too, was balanced across groups, the relatively low percentage 
of male participants may limit the generalizability of the results. Finally, MBSR’s quicker 
impact might have been due in part to the doctoral level training of the facilitators in that 
arm, as opposed to the master’s level facilitators in the PES arm. However, the fidelity 
checks were uniformly high, and in fact a little higher in the PES arm.
CONCLUSIONS
Our trial provides promising support for MBSR as well as PES for the treatment of CRF. 
This is especially important given the current lack of evidenced-based pharmacological 
therapies for CRF. Phase 3 trials comparing these potentially efficacious behavioral 
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treatments compared to UC are warranted. When more than one efficacious behavioral 
treatment exists, patient preferences should play a central role.
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Fig. 1. 
CONSORT diagram for trial accrual, intervention delivery, and data collection
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Table 3
Demographic and Medical Characteristics
MBSR
n=35
Education/Support
n=36 p-value
Demographic Characteristics
Age, mean (SD) 56.9 (9.9) 56.4 (12.7) 0.85
Female, % 94.3 86.1 0.43
White, % 77.1 63.9 0.22
Married/Partnered, % 62.9 47.2 0.19
College degree, % 42.9 44.4 0.89
Employed, % 51.4 52.8 0.91
Comfortable income, % 62.9 41.7 0.07
Medical Characteristics
Cancer type 0.35
 Breast cancer, % 51.7 48.3
 Colorectal cancer, % 36.4 63.6
Cancer stage at diagnosis, % 0.75
 0 12.8 5.3
 I 41.0 36.8
 II 20.5 23.7
 III 20.5 29.0
Years since cancer treatment completion, mean (SD) 2.2 (1.4) 2.5 (1.6) 0.48
Chemotherapy, % 65.7 80.6 0.16
Radiation, % 80.0 75.0 0.61
Chemo-radiation, % 45.7 55.6 0.41
Current endocrine therapy, % 46.0 46.0 1.00
Co-morbid medical conditions in addition to cancer, mean (SD) 1.80 (1.5 ) 1.7(1.2) 0.75
Current Mental Health Treatment, % 17.1 22.2 0.59
Past Mental Health Treatment, % 25.7 41.7 0.16
Note. MBSR=Mindfulness-Based Stress Reduction. SD=standard deviation.
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